Results 61 to 70 of about 67,119 (304)
Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells, B-
Erin H. Yang +5 more
doaj +1 more source
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng +5 more
wiley +1 more source
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells [PDF]
To the editor: The recently approved anti-CD38 monoclonal antibody daratumumab (DARA) provides a unique therapeutic strategy that more selectively targets plasma cells in patients with plasma cell myeloma.[1][1][⇓][2][⇓][3][⇓][4][⇓][5]-[6][6] While DARA recognizes and removes ...
Harold C. Sullivan +13 more
openaire +1 more source
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao +15 more
wiley +1 more source
Interference of daratumumab with compatibility testing in blood bank
Plasma cell myeloma accounts for 1% of malignant tumors and 10%–15% of hematopoietic neoplasms. Daratumumab (DARA), a novel targeted immunotherapy drug, was approved by the Food and Drug Administration to treat relapsed/refractory multiple myeloma. DARA,
Rani Premkumar, Siva Deepthi
doaj +1 more source
Background: CD38+ NK (CD3− CD16+ CD38+ CD56+) cells were increased in rheumatoid arthritis (RA), which suppressed Treg cell differentiation. This study explored how CD38+ NK cells regulated CD4+ T-cell differentiation into Treg cells in RA.
Hongxing Wang +3 more
doaj +1 more source
Catalysis-based inhibitors of the calcium signaling function of CD38
CD38 is a signaling enzyme responsible for catalyzing the synthesis of cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate; both are universal Ca(2+) messenger molecules.
Hao, Q +29 more
core +1 more source
Современные представления о роли CD38 в патогенезе бронхиальной астмы
Current view on a role of CD38 for pathogenesis of bronchial asthma.Современные представления о роли CD38 в патогенезе бронхиальной ...
I. V. Demko +9 more
core +1 more source
Our meta‐analysis showed significant improvement of PFS with lenalidomide, proteasome inhibitors, and CD38‐based therapies. A significant OS benefit was noted only with lenalidomide in transplant‐eligible (TE) patients, while CD38‐directed therapy showed a trend toward improved OS.
Heinz Ludwig +25 more
wiley +1 more source
Pristane (5 mL/kg) induced a robust systemic lupus erythematosus (SLE)‐like phenotype in Macaca fascicularis, marked by elevated antinuclear antibody (ANA) levels and systemic clinical, hematological, and biochemical changes. This model closely reflects human SLE and provides a translational platform for disease studies and therapeutic evaluation ...
Jonny Jonny +12 more
wiley +1 more source

